Investigating the effects and underlying mechanisms of glycosylation sites on the immunogenicity of COVID-19 vaccines [0.03%]
糖基化位点对新冠肺炎疫苗免疫原性影响及其机制研究
Heru Wang,Xiang Li,Peng He et al.
Heru Wang et al.
Glycosylation plays a pivotal role in modulating the structure and immunogenicity of viral antigens. Three glycosylation sites on the receptor-binding domain (RBD) of SARS-CoV-2, including N331, N343 (N-linked), and T323 (O-linked), are hig...
A specific stem cell program and CD112 immunological axis dysfunctions underpinning monosomy 7-associated myeloid neoplasms [0.03%]
基于染色体7单体相关骨髓肿瘤的特定干细胞程序和CD112免疫轴功能障碍
Anair Graciela Lema Fernandez,Carlotta Nardelli,Martina Quintini et al.
Anair Graciela Lema Fernandez et al.
Monosomy 7 (-7) is occurring as isolated change or in complex karyotypes in 10-20% of myeloid neoplasms with poor prognosis. Although several genes mapping at chromosome 7 have been involved in pathogenetic mechanisms, the -7 molecular land...
The evolving global landscape of first-in-class oncology drug innovation [0.03%]
不断演变的first-in-class肿瘤药物创新全球格局
Xiangyun Mao,Zhaoqing Wang,Shu Kong et al.
Xiangyun Mao et al.
First-in-class (FIC) oncology drugs-defined by their novel mechanisms of action or targeting of previously unaddressed molecular targets-have emerged as a leading force in cancer therapeutic innovation. In this Review, we delineate the glob...
SSTNIV, a syndecan-1-targeting peptide chimera, reverses immune suppression and inhibits myeloma progression [0.03%]
一种新的靶向 syndecan-1 嵌合肽 SSTNIV 反转免疫抑制并抑制多发性骨髓瘤进展
Oisun Jung,DeannaLee M Beauvais,Gavril L Ibaan et al.
Oisun Jung et al.
Despite therapeutic advances, multiple myeloma (MM) remains incurable, largely due to relapse and the emergence of drug resistance driven by clonal evolution and alterations in the bone marrow (BM) microenvironment that support tumor surviv...
Naresh L Selokar,Wilfried A Kues
Naresh L Selokar
iS2C2: a cointelligent platform for mechanistic discovery of disease cellular crosstalk [0.03%]
iS2C2：一种用于疾病细胞串扰机制发现的协同智能平台
Jianting Sheng,Ju Young Ahn,Li Yang et al.
Jianting Sheng et al.
Large language models (LLMs) have demonstrated impressive capabilities in summarization, reasoning, and content generation, yet their inability to directly interpret large-scale omics data has limited their utility in data-driven hypothesis...
Acute hemodynamic effects of TPN171H in pulmonary arterial hypertension: a randomized, controlled, phase 2a trial [0.03%]
TPN171H治疗肺动脉高压的急性血流动力学效应：2期随机对照试验
Yu-Ping Zhou,Lu-Hong Qiu,Wei Ma et al.
Yu-Ping Zhou et al.
Pulmonary arterial hypertension (PAH) has a poor prognosis despite available treatments. TPN171H, structurally modified from traditional Chinese medicine (Epimedium), was reported to have a high affinity for phosphodiesterase type 5 and exh...
ADAMTS4 elicits myeloid-derived immune cell recruitment and liver fibrogenesis in metabolic dysfunction-associated steatotic liver disease [0.03%]
ADAMTS4通过募集髓系衍生的免疫细胞诱导代谢功能障碍相关性肝脂肪变性疾病的肝纤维化
Jeongwoo Park,Taeeung Kim,Wan Seob Shim et al.
Jeongwoo Park et al.
A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) has been implicated in arthritis and lung fibroblast activation; however, its role in liver homeostasis and fibrogenesis remains largely unexplored. Here, we investi...
Antagonistic pleiotropy in disease tolerance: Foxo1-Trim63 axis as double-edged sword in age-dependent sepsis [0.03%]
疾病耐受性的拮抗多效性：Foxo1-Trim63轴在年龄依赖性脓毒症中的双刃剑作用
Unbin Chae,Jin-Man Kim,Young-Ho Park
Unbin Chae
Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial [0.03%]
sintilimab（pd-1抑制剂）联合仑伐替尼作为新辅助治疗后序贯手术(silenese研究) 治疗不可切除的局部晚期肝细胞癌：一项Ⅱ期、扩展临床试验
Shichun Lu,Wenwen Zhang,Junfeng Li et al.
Shichun Lu et al.
Our previous findings demonstrated the promising antitumor activity and manageable safety of sintilimab-lenvatinib conversion therapy. The current study aimed to evaluate long-term survival outcomes in patients with unresectable hepatocellu...